Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy

Purpose: The half-life of the antiangiogenic molecule endostatin that has been used in clinical trial is short (∼2 h). In addition, ∼50% of the clinical grade endostatin molecules lack four amino acids at their NH 2 termini. Lack of these amino acids gives rise to a molecule that is devoid of zinc,...

Ausführliche Beschreibung